SILO Pharma Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Quarterly Report (Form 10-Q) | 13 Nov 2026 |
Monitoring Framework
Key Performance Indicators
SPC-15 Clinical Trial Initiation QuarterlyTarget: First-in-human Phase 1 clinical trial initiation
Cash and Cash Equivalents Quarterly3.9MTarget: Maintain sufficient liquidity for planned R&D operations
Working Capital Quarterly6.1MTarget: Maintain positive working capital to support ongoing clinical programs
Watch Items
- FDA Investigational New Drug (IND) Application for SPC-15Trigger: IND submission and subsequent FDA approvalAction: Monitor regulatory filings and correspondence with the FDA regarding the planned Phase 1 trial.
- Nasdaq Minimum Bid Price ComplianceTrigger: Closing bid price falling below $1.00 for 30 consecutive business daysAction: Monitor stock price stability following the 1-for-15 reverse stock split executed on June 2, 2026.
- Digital Assets Treasury Strategy VolatilityTrigger: Significant write-downs or impairments on cryptocurrency holdings (Bitcoin, Ethereum, Solana, ResearchCoin)Action: Review quarterly financial statements for unrealized losses and impairment charges on digital assets.
Research as of 20 Jun 2026